Palisade Bio Reports Q1 2026 Financial Results

What Happened Palisade Bio, Inc. announced its financial results for the three months ended March 31, 2026 in a press release and filed a Form 8-K on May 12, 2026 to disclose those results (Exhibit 99.1). The 8-K states the press release is attached and incorporated by reference; the filing is signed by CEO J.D. Finley.

Key Details

• Filing date: May 12, 2026 (Form 8-K Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Disclosure format: press release attached as Exhibit 99.1 and incorporated by reference.
• Signature: filed and signed by J.D. Finley, Chief Executive Officer.

Why It Matters Quarterly financial results are a primary source for assessing Palisade Bio’s recent operating performance, revenue trends, expense levels and cash position — all factors that can influence investor decisions and the stock price. The 8-K itself references the press release for the specific figures and narrative; investors should read Exhibit 99.1 and the company’s forthcoming SEC filings (e.g., 10-Q) for the full financials and commentary.